Categories
Breast Cancer

DESTINY-Breast04: practice-changing results for HER2-low breast cancer [Video]

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, speaks on the practice-changing findings from DESTINY-Breast04 (NCT03734029), a Phase III study that demonstrated improved survival of patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan compared to standard chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

MagnetisMM-3: elranatamab in relapsed/refractory multiple myeloma [Video]

Alexander M. Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses safety results from the MagnetisMM-3 trial (NCT04649359), a Phase II, open-labeled, multicenter, non-randomized trial evaluating elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody in patients with relapsed/refractory multiple myeloma. Patients enrolled were refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 antibody. Preliminary results of MagnetisMM-3 in patients with relapsed/refractory myeloma and no prior BCMA-targeted treatment suggest that 76 mg of elranatamb adminstered once weekly with a 2-step-up priming regimen is well tolerated, with no grade 3 cytokine release syndrome or immune effector cell-assciated neurotoxicity syndrome (ICANS) observed. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

The role of checkpoint inhibitors in classical Hodgkin lymphoma [Video]

Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, describes the efficacy of checkpoint inhibitors in treating classical Hodgkin lymphoma, which is the current standard of care in patients who have progressed from autologous stem cell transplantation. Multiple trials have demonstrated durable responses in patients receiving checkpoint inhibitors such as pembrolizumab with ICE or GVD chemotherapy and nivolumab with brentuximab vedotin as a salvage regimens. Further research will additionally reveal the potential of checkpoint inhibitors in the frontline setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

RIC vs MAC in MRD-positive & MRD-negative patients with AML [Video]

Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, comments on the use of reduced-intensity conditioning (RIC) and myeloablative conditioning (MAC) in patients with acute myeloid leukemia (AML) who are measurable residual disease (MRD)-positive or MRD-negative. Whilst studies have suggested that MRD-positive patients should be treated with MAC, it is necessary to conduct a prospective study to determine the best conditioning regimen for MRD-negative patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

CAR-T, bispecifics and MRD: how is treatment for multiple myeloma evolving? [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, gives his thoughts on how the treatment of multiple myeloma could evolve – including the continued use of CAR-Ts, the use of bispecific antibodies for maintenance therapy, and the importance of measurable residual disease (MRD) for patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Skin Cancer

I-TACKLE: IO followed by cetuximab in la/metastatic cutaneous squamous cell carcinomas [Video]

Paolo Bossi, MD, University of Brescia, Brescia, Italy, presents findings from the open-label, non-randomized Phase II I-TACKLE trial (NCT03666325) of pembrolizumab and cetuximab in patients with locally advanced/metastatic cutaneous squamous cell carcinomas (cSCC). 43 patients were enrolled and initially received pembrolizumab, with 23 patients also receiving cetuximab after acquiring resistance to pembrolizumab. The addition cetuximab resulted in 38% response with the addition of cetuxumab. Additionally, an acceptable safety profile reported. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

CAR-T updates in myeloma [Video]

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, shares some insights into recent updates in CAR-T therapy for the treatment of multiple myeloma. Prof. Raje first discusses how the approval of ciltacabtagene autoleucel (cilta-cel) has improved options for triple-class refractory and penta-refractory patients, and further explains the promise of idecabtagene vicleucel (ide-cel) and the importance of real-world data. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Quadruplet induction therapy as a new standard of care in multiple myeloma [Video]

Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, comments on the tolerability and efficacy of quadruplet induction regimens in transplant-eligible and transplant-ineligible patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Current & emerging treatments for patients with triple-class refractory multiple myeloma [Video]

Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, outlines current and emerging treatment strategies for patients with triple-class refractory multiple myeloma, which currently include belantamab mafodotin and selinexor. The recent introduction and development of CAR-T therapy and bispecific antibodies in this setting is changing the treatment landscape of patients with triple-class refractory disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Antibodies in multiple myeloma and their impact on treatment [Video]

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses recent advances in the use of antibodies for the treatment of multiple myeloma, highlighting the promise of monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), as well as bispecifics. Prof. Raje first comments on the movement of mAbs into the frontline setting and advances in quadruplet regimens. Following this, Prof. Raje highlights the DETERMINATION trial (NCT01208662), and further discusses the use of ADCs, such as belantamab mafodotin, as a single agent and in combination with other agents. To conclude, Prof. Raje discusses the promise of bispecific antibodies including teclistamab and elranatamab, and their place in the myeloma treatment landscape. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Toxicities associated with brentuximab vedotin in pediatric and adolescent Hodgkin lymphoma [Video]

Kara Kelly, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, provides an overview of the toxicities associated with brentuximab vedotin in adolescent and pediatric patients with Hodgkin lymphoma. Concerns of myelosuppression, infection risk and peripheral neuropathy which are associated with brentuximab vedotin administration in adults, is reduced in adolescent and pediatric populations. Dr Kelly discusses the next steps evaluating the use of brentuximab vedotin in pediatric settings, and highlights reduced radiotherapy as an area of unmet need in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Skin Cancer

Expanded efficacy and safety analyses from CheckMate 648 [Video]

First-line chemotherapy for advanced esophageal squamous cell carcinoma (ESCC) results in poor outcomes, In this interview, Ian Chau, MD, FRCP, The Royal Marsden NHS Foundation, London, UK, discusses findings from CheckMate 648 (NCT03143153), an open-label Phase III study evaluating nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced ESCC, which previously reported overall survival benefit for both nivolumab + chemotherapy and nivolumab + ipilimumab. In this expanded report with 13-month minimum follow up, nivolumab + chemotherapy and nivolumab + ipilimumab demonstrated favorable PFS2 and a higher proportion of patients with prolonged duration of response vs chemotherapy alone, as well as acceptable safety profiles. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.